A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity
Latest Information Update: 23 Aug 2023
At a glance
- Drugs GX G6 (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Sponsors CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Most Recent Events
- 22 Aug 2023 New trial record
- 18 Aug 2023 Planned End Date changed from 30 Apr 2024 to 30 Apr 2025.
- 18 Aug 2023 Planned primary completion date changed from 31 Jan 2024 to 31 Jan 2025.